US EditionPublished • loading... • Updated
Blood test could bolster brain cancer survival rates
The Phenotype Analyzer Chip detects active EGFR biomarkers in under an hour using just 100 µL of blood and has been validated in over 40 brain cancer patients.
- On Saturday, University of Queensland researchers published in Science Advances on the Phenotype Analyzer Chip that reads glioblastoma treatment response by analysing extracellular blood particles.
- High-Grade glioblastoma in Australia affects up to 1,500 diagnosed annually with poor survival under 14 months; last year 1,640 died and over 2,000 cases were recorded, funded by the Mark Hughes Foundation and University of Newcastle, Mark Hughes Foundation Centre for Brain Cancer Research.
- Running one test takes under an hour, requires 100 microlitres of blood, and uses a biochip with an electrokinetic sensor detecting active Epidermal Growth Factor Receptors; each biochip costs less than $2, with reusable automation.
- After validation in more than 40 patients, clinical trials will test the device, which clinicians say helps regional patients by enabling quicker treatment adjustments.
- Beyond glioblastoma, Chang said `Our technique is not specific to glioblastoma, but it was particularly appropriate to start with it because of how deadly it is and the lack of early screening tests available`, and Fay added that `what's particularly exciting here is we're getting a signal coming from the brain, which we can pick up in half a millilitre of blood`.
Insights by Ground AI
16 Articles
16 Articles
Newcastle Herald+2 Reposted by 2 other sources
'A window to the brain': crucial blood test developed with Mark Hughes funds
A new blood test for brain cancer was developed with the biobank of the Mark Hughes Foundation Centre for Brain Cancer Research at the University of Newcastle.
·Newcastle, Australia
Read Full Article
Researchers develop affordable, rapid blood test for brain cancer
Researchers have developed a novel, automated device capable of diagnosing glioblastoma, a fast-growing and incurable brain cancer, in less than an hour. The average glioblastoma patient survives 12-18 months after diagnosis.
·United States
Read Full Article
A simple blood test has the potential to improve the lives of brain cancer patients and increase their already extremely low survival rate.
Coverage Details
Total News Sources16
Leaning Left9Leaning Right1Center3Last UpdatedBias Distribution69% Left
Bias Distribution
- 69% of the sources lean Left
69% Left
L 69%
C 23%
Factuality
To view factuality data please Upgrade to Premium
